Innohep (Tinzaparin Sodium)

Tinzaparin sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This blocks the conversion of prothrombin to thrombin and the formation of fibrin, interrupting the coagulation cascade and preventing clot propagation.

The dose of Innohep is individualized by the prescribing clinician based on the patient’s indication, weight, renal function and bleeding risk. The prescriber determines the appropriate subcutaneous injection volume and frequency in accordance with approved labeling and clinical guidelines.

Innohep is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Use while breastfeeding is not recommended unless clearly needed.

To request Innohep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with unfractionated heparin, tinzaparin offers more predictable pharmacokinetics, once‑daily subcutaneous dosing and a lower risk of heparin‑induced thrombocytopenia. Relative to other low molecular weight heparins, its anti‑Xa activity is similar, but dosing and monitoring requirements may differ, so selection depends on clinical context and physician preference.

Innohep should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the vials in the original packaging until use, and discard any product that appears discolored or contains particles.

Innohep is supplied as a sterile solution for subcutaneous injection. The prescriber selects the injection site, typically the abdomen or thigh, and administers the dose using a sterile needle and syringe. Patients should be instructed on proper technique and rotation of injection sites to minimize local reactions.

The most serious adverse events include major hemorrhage, heparin‑induced thrombocytopenia (HIT) and spinal or epidural hematoma, especially when neuraxial anesthesia is performed. Prompt recognition of unusual bleeding, sudden drop in platelet count, or neurological symptoms is essential for immediate medical evaluation.

Innohep is contraindicated in patients with known hypersensitivity to tinzaparin or other heparins, active major bleeding, severe uncontrolled hypertension, or a history of heparin‑induced thrombocytopenia. Caution is also advised in individuals with severe renal impairment, recent intracranial surgery, or those receiving concurrent anticoagulants unless specifically indicated.